The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis.
Marie-Justine Paillard
No relevant relationships to disclose
Elsa Curtit
No relevant relationships to disclose
Virginie Nerich
No relevant relationships to disclose
Laurent Cals
No relevant relationships to disclose
Fernando Bazan
No relevant relationships to disclose
Laura Mansi
No relevant relationships to disclose
Nathalie Meneveau
No relevant relationships to disclose
Philippe Montcuquet
No relevant relationships to disclose
Erion Dobi
No relevant relationships to disclose
Loic Chaigneau
No relevant relationships to disclose
Hamadi Almotlak
No relevant relationships to disclose
Antoine Thiery-Vuillemin
No relevant relationships to disclose
Cristian Villanueva
No relevant relationships to disclose
Xavier B. Pivot
Consultant or Advisory Role - Eisai
Honoraria - Eisai